AM-Pharma Announces the Appointment of Chairman
Complete the form below to unlock access to ALL audio articles.
AM-Pharma B.V. has announced the appointment of Dr Russell Greig as Chairman of the Supervisory Board.
Dr Greig served nearly three decades with pharmaceutical giant GlaxoSmithKline, most recently as President of SR One, GSK’s Corporate Venture Group.
Prior to joining SR One, he served as President of GSK's Pharmaceuticals International from 2003 to 2008 and also served on the GSK Corporate Executive Team.
Dr Greig originally joined GSK (then SmithKline & French) in 1980 in the Departments of Tumor and Cell Biology. In 1991, following the merger with Beecham, he was appointed Vice President, Project Management.
From 1993 to 1996, he served as Vice President and Director of Advanced Technologies in Genetics with special responsibility for managing collaborations with The Institute of Genomic Research and Human Genome Sciences.
In 1996, Dr Greig joined SmithKline Beecham's European Pharmaceutical Operations as Vice President and Director of European Market Development, and was later appointed Managing Director and General Manager of SmithKline Beecham's UK Pharmaceuticals.
Following the merger of SmithKline Beecham with GlaxoWellcome in 2000, he returned to the United States as Senior Vice President for Worldwide Business Development.
At the same time, Eric Claassen will step down from the board. Eric Claassen has been chairman of AM-Pharma for more than 10 years and shepherded the company through its initial phase of development, leading to AM-Pharma’s D-round.
This €29.2m round announced in September 2011 was the largest private financing round in the Netherlands for a biotech firm ever.
Eric Claassen said; “It feels good to hand over the reins of AM Pharma now it is well financed and backed by a broad professional syndicate. The new board will bring AM Pharma to well-deserved success.”
Dr Greig commented: “AM-Pharma is a company that I believe will be “one to watch”. They have embarked on a firm strategy to address the unmet medical need of treating Acute Kidney Injury. The positive clinical data and blockbuster market potential coupled with a solid development plan from an experienced management team, have all convinced me that AM-Pharma is poised to make a real difference in a field that has long been neglected.”
Erik van der Berg, CEO of AM-Pharma, added: “Russell combines senior level international management expertise with a large pharma network and a dynamic outlook. We are delighted to have someone of this calibre being introduced by the new investors and leading us at this pivotal stage in our corporate development.”